Market Access/ News/ News/ News/ Sales and Marketing Amarin hit hard as generics loom for fish oil drug Vascepa Phil Taylor Amarin, cardiovascular, Dr Reddy's, generic, Hikma, litigation, Vascepa 0 Comment Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share X Amarin hit hard as generics loom for fish oil drug Vascepa https://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
Market Access/ News/ News Amarin gets FDA panel okay for new Vascepa indication Phil Taylor Amarin, cardiovascular disease, fda, Vascepa 0 Comment Amarin is on course to significantly increase the number of patients eligible for treatment with its purified fish Share X Amarin gets FDA panel okay for new Vascepa indication https://pharmaphorum.com/news/amarin-gets-fda-panel-okay-for-new-vascepa-indication/
Market Access/ News/ News Amarin’s Vascepa gets priority review for cardiovascular label expansion George Underwood Amarin, cardiovascular, Vascepa 0 Comment Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results Share X Amarin’s Vascepa gets priority review for cardiovascular label expansion https://pharmaphorum.com/news/amarins-vascepa-gets-priority-review-for-cardiovascular-label-expansion/
Amarin, cardiovascular, Dr Reddy's, generic, Hikma, litigation, Vascepa
0 Comment
